Search Results
Keyword:Atom High-Tech
Atom High-Tech Signs Memorandum of Cooperation with Cambodia's Calmette Hospital and Others to Advance Nuclear Medicine Capacity Building
On September 4, Atom High-Tech, Cambodia's Calmette Hospital, and FFS Company held a trilateral memorandum of cooperation signing ceremony in Beijing. Huo Yingying, Deputy Secretary of the Party Committee of China Isotope & Radiation Corporation (CIRC), attended and delivered a speech, while Zhang Yiming, Secretary of the Party Committee and Chairman of Atom High-Tech, signed on behalf of the company. Established in 1950, Calmette Hospital is one of Cambodia's largest and most technologically advanced public hospitals and serves as a national referral center. It undertakes three core missions: delivering high-quality medical services, training health professionals, and conducting medical research. Currently, the hospital is actively advancing its nuclear medicine capacity by establishing the country's first nuclear medicine department, further improving its oncology diagnosis and treatment and molecular imaging service systems...
2026-09-07
Atom High-Tech Adds New Radiopharmaceutical Production Base in Changchun
The Jilin Provincial Medical Products Administration issued a public notice on August 21 stating that, in accordance with the Drug Administration Law of the People's Republic of China, the Regulations on the Administration of Radiopharmaceuticals, the Measures for the Supervision and Administration of Drug Production, and other relevant provisions, following on-site inspection and review approval, it intends to issue the Radiopharmaceutical Production License to Changchun Atom High-Tech Pharmaceutical Co., Ltd. The public notice period is 5 working days, subject to public supervision. The notice information shows that the registered address of Changchun Atom High-Tech Pharmaceutical Co., Ltd. is located at No. 770 Shengye Road, Beihu Science and Technology Development Zone, Changchun City, Jilin Province, and the proposed production address for the license is consistent with the registered address. The proposed production scope for this license is small-volume injections for in vivo radiopharmaceuticals, involving products such as Sodium Pertechnetate [99mTc] Injection, Technetium [99mTc] Methylenediphosphonate Injection, Technetium [99mTc] Methoxyisonitrile Injection, Technetium [99mTc] Pentetate Injection, Technetium [99mTc] Ethyl Cysteinate Dimer Injection, and Technetium [99mTc] Etifenin Injection.
2026-08-24
Atom High-Tech and CNNC Headway Visit Tsinghua University for Business Cooperation Exchange
On August 17, Luo Xu, General Manager of Atom High-Tech, and Liu Wen, Chairman of CNNC Headway, led a delegation to Tsinghua University for a business cooperation exchange with the School of Biomedical Engineering. Hu Ye, Dean of the School of Biomedical Engineering, and Ma Kai, Associate Professor of the School, attended the exchange. The visit aimed to leverage the research and talent advantages of a top-tier university, promote deep integration of industry, academia, and research, and jointly explore new cooperation opportunities in the fields of nuclear medicine and biomedical engineering. During the exchange meeting, Atom High-Tech and CNNC Headway respectively introduced their corporate development histories, core business layouts, and future strategic plans. Subsequently, Dean Hu Ye and Associate Professor Ma Kai respectively introduced...
2026-08-21